• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Contineum Therapeutics Inc.

    5/14/25 4:08:01 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    cont20250331_10q.htm
    0001855175 Contineum Therapeutics, Inc. false --12-31 Q1 2025 0.001 0.001 200,000,000 200,000,000 19,142,377 19,142,377 19,125,377 19,125,377 0.001 0.001 20,000,000 20,000,000 6,729,172 6,729,172 6,729,172 6,729,172 0.001 0.001 10,000,000 10,000,000 0 0 0 0 19,142,377 6,729,172 0 10 5 5 3 5.6 1 false false false false Basic and diluted per share amounts are the same for Class A and Class B shares. Other segment items primarily include change in fair value of warrant liability and other expense, net. 00018551752025-01-012025-03-31 xbrli:shares 00018551752025-05-09 thunderdome:item iso4217:USD 00018551752025-03-31 00018551752024-12-31 iso4217:USDxbrli:shares 0001855175us-gaap:CommonClassAMember2025-03-31 0001855175us-gaap:CommonClassAMember2024-12-31 0001855175us-gaap:CommonClassBMember2025-03-31 0001855175us-gaap:CommonClassBMember2024-12-31 00018551752024-01-012024-03-31 0001855175us-gaap:CommonStockMember2024-12-31 0001855175us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001855175us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 0001855175us-gaap:RetainedEarningsMember2024-12-31 0001855175us-gaap:CommonStockMember2025-01-012025-03-31 0001855175us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0001855175us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31 0001855175us-gaap:RetainedEarningsMember2025-01-012025-03-31 0001855175us-gaap:CommonStockMember2025-03-31 0001855175us-gaap:AdditionalPaidInCapitalMember2025-03-31 0001855175us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31 0001855175us-gaap:RetainedEarningsMember2025-03-31 0001855175ctnm:ConvertiblePreferredStockTemporaryEquityMember2023-12-31 0001855175us-gaap:CommonStockMember2023-12-31 0001855175us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001855175us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001855175us-gaap:RetainedEarningsMember2023-12-31 00018551752023-12-31 0001855175ctnm:ConvertiblePreferredStockTemporaryEquityMember2024-01-012024-03-31 0001855175us-gaap:CommonStockMember2024-01-012024-03-31 0001855175us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001855175us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 0001855175us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001855175ctnm:ConvertiblePreferredStockTemporaryEquityMember2024-03-31 0001855175us-gaap:CommonStockMember2024-03-31 0001855175us-gaap:AdditionalPaidInCapitalMember2024-03-31 0001855175us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 0001855175us-gaap:RetainedEarningsMember2024-03-31 00018551752024-03-31 xbrli:pure 0001855175ctnm:ReverseStockSplitMember2024-04-012024-04-01 0001855175us-gaap:IPOMember2024-04-052024-04-05 0001855175us-gaap:IPOMember2024-04-05 0001855175us-gaap:OverAllotmentOptionMember2024-04-192024-04-19 0001855175us-gaap:IPOMember2024-04-062024-04-19 00018551752024-04-09 0001855175us-gaap:CommonClassAMember2024-04-09 0001855175us-gaap:CommonClassBMember2024-04-09 0001855175us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-31 0001855175us-gaap:CertificatesOfDepositMember2025-03-31 0001855175us-gaap:CorporateDebtSecuritiesMember2025-03-31 0001855175us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-03-31 0001855175us-gaap:ForeignGovernmentDebtSecuritiesMember2025-03-31 0001855175us-gaap:AssetBackedSecuritiesMember2025-03-31 0001855175us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-31 0001855175us-gaap:CertificatesOfDepositMember2024-12-31 0001855175us-gaap:CorporateDebtSecuritiesMember2024-12-31 0001855175us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-12-31 0001855175us-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-31 0001855175us-gaap:AssetBackedSecuritiesMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2025-03-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2025-03-31 0001855175us-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-12-31 0001855175us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-12-31 0001855175us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-12-31 0001855175us-gaap:MoneyMarketFundsMember2025-03-31 0001855175us-gaap:MoneyMarketFundsMember2024-12-31 0001855175us-gaap:EmployeeStockOptionMember2025-03-31 0001855175us-gaap:EmployeeStockOptionMember2024-12-31 0001855175ctnm:The2024EquityIncentivePlanMember2025-03-31 0001855175ctnm:The2024EquityIncentivePlanMember2024-12-31 0001855175ctnm:CommonStockWarrantMember2025-03-31 0001855175ctnm:CommonStockWarrantMember2024-12-31 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2025-03-31 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2024-12-31 0001855175ctnm:The2024EquityIncentivePlanMember2024-01-01 0001855175ctnm:The2024EquityIncentivePlanMember2024-03-012024-03-31 0001855175us-gaap:EmployeeStockOptionMemberctnm:The2024EquityIncentivePlanMembersrt:MinimumMember2024-03-012024-03-31 utr:Y 0001855175us-gaap:EmployeeStockOptionMemberctnm:The2024EquityIncentivePlanMember2024-03-012024-03-31 00018551752024-01-012024-12-31 0001855175us-gaap:EmployeeStockOptionMember2025-01-012025-03-31 0001855175us-gaap:EmployeeStockOptionMember2024-01-012024-03-31 0001855175us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-31 0001855175us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-31 0001855175us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-31 0001855175us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-31 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2025-01-012025-03-31 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2024-01-012024-03-31 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMembersrt:MinimumMember2024-04-09 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMembersrt:MaximumMember2024-04-09 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2024-04-09 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2025-03-31 0001855175ctnm:EmployeeStockPurchasePlanThe2024EsppMember2024-04-092024-04-09 0001855175ctnm:JJLicenseAgreementMember2023-02-012023-02-28 0001855175ctnm:JJLicenseAgreementMember2023-02-28 0001855175ctnm:JjdcMemberctnm:PreferredStockPurchaseAgreementMember2023-04-012023-04-30 0001855175ctnm:JjdcMemberctnm:PreferredStockPurchaseAgreementMember2023-04-30 0001855175ctnm:JJLicenseAgreementMember2023-05-012023-05-31 0001855175ctnm:ScienceCenterDriveLeaseMember2018-03-31 0001855175ctnm:ScienceCenterDriveLeaseMembersrt:MaximumMember2018-03-31 0001855175ctnm:ScienceCenterDriveLeaseMember2021-06-30 0001855175ctnm:GeneralAtomicsCourtLeaseMember2024-10-01 00018551752024-10-012024-10-01 00018551752024-10-01 0001855175ctnm:NewLeaseAgreementMember2025-03-31 0001855175us-gaap:ConvertiblePreferredStockMember2025-01-012025-03-31 0001855175us-gaap:ConvertiblePreferredStockMember2024-01-012024-03-31 0001855175us-gaap:EmployeeStockOptionMember2025-01-012025-03-31 0001855175us-gaap:EmployeeStockOptionMember2024-01-012024-03-31 0001855175ctnm:PreferredStockWarrantMember2025-01-012025-03-31 0001855175ctnm:PreferredStockWarrantMember2024-01-012024-03-31 0001855175ctnm:CommonStockWarrantMember2025-01-012025-03-31 0001855175ctnm:CommonStockWarrantMember2024-01-012024-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:PIPE791Member2025-01-012025-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:PIPE791Member2024-01-012024-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:PIPE307Member2025-01-012025-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:PIPE307Member2024-01-012024-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:CTX343Member2025-01-012025-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:CTX343Member2024-01-012024-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:DiscoveryProgramsMember2025-01-012025-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:DiscoveryProgramsMember2024-01-012024-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:UnallocatedInternalCostsMember2025-01-012025-03-31 0001855175us-gaap:OperatingSegmentsMemberctnm:UnallocatedInternalCostsMember2024-01-012024-03-31 0001855175us-gaap:OperatingSegmentsMember2025-01-012025-03-31 0001855175us-gaap:OperatingSegmentsMember2024-01-012024-03-31 0001855175ctnm:NewLeaseAgreementMember2025-01-012025-03-31
     

     

    Table of Contents



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     


    FORM 10-Q

     


     

    (Mark One)

    ☒

    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the quarterly period ended March 31, 2025

     

    OR

     

    ☐

    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from _______ to _______

     

    Commission File Number: 001-42001

     


    Contineum Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)


     

    Delaware

    27-1467257

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

     

    3565 General Atomics Court, Suite 200

    San Diego, California

    92121

    (Address of principal executive offices)

    (Zip Code)

     


    (858) 333-5280

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name, former address and former fiscal year, if changed since last report)

     


     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Class A Common Stock, $0.001 par value per share

     

    CTNM

     

     

    The Nasdaq Stock Market LLC

    (Nasdaq Global Select Market)

     

     

    Table of Contents

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

        

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

        

    Emerging growth company

    ☒

      

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

     

    As of May 9, 2025, the registrant had 25,871,549 total shares outstanding, of which there were 19,142,377 shares of Class A common stock, $0.001 par value per share, outstanding and 6,729,172 shares of Class B common stock, $0.001 par value per share, outstanding.

     

     

    Table of Contents

    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

     

    This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

     

    The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other similar expressions are intended to identify forward looking statements. Forward-looking statements contained in this report include, but are not limited to, statements about:

     

    • the likelihood of our clinical trials demonstrating the safety and efficacy of our drug candidates;

     

    • the timing and progress of our current clinical trials, the expected results of these clinical trials and the timing of initiation of our planned and future clinical trials;

     

    • our plans relating to the clinical development of our current and future drug candidates, including the size, number and disease indications to be evaluated;

     

    • Janssen Pharmaceutica NV, a Johnson & Johnson (“J&J”) company’s, plans related to the clinical development of PIPE-307;

     

    • our clinical translational approach, and our ability to identify and develop drug candidates that can potentially treat neuroscience, inflammation and immunology (“NI&I”) diseases by targeting biological pathways associated with specific clinical impairment to alter the course of disease;

     

    • the size of the market opportunities for our drug candidates;

     

    • the rate and degree of market acceptance and clinical utility of our drug candidates;

     

    • our plans relating to commercializing our drug candidates, if approved;

     

    • the success of competing therapies and technologies that are or may become available;

     

    • the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our drug candidates;

     

    • the timing or likelihood of regulatory filings and approval for our drug candidates;

     

    • our ability to obtain and maintain regulatory approval of our drug candidates and our drug candidates to meet existing or future regulatory standards;

     

    • our plans relating to the further development and manufacturing of our drug candidates, including additional indications for which we may pursue;

     

    • our ability to successfully identify and complete transactions to in-license or otherwise acquire additional drug candidates, technologies, products or businesses;

     

    • our ability to attract and to enter into commercial arrangements with third parties who have development, regulatory, manufacturing and commercialization expertise;

     

    • our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available, as well as our ability to secure and maintain intellectual property regulatory rights and regulatory protections;

     

    • our ability to retain our senior management;

     

    • the need to hire additional personnel and our ability to attract and retain such personnel;

     

    • the accuracy of our estimates regarding our operating runway, expenses, capital requirements and needs for additional financing;

     

     

    Table of Contents

     

    • the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;

     

    • the period during which we expect we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”) or a smaller reporting company;

     

    • our anticipated use of our existing cash, cash equivalents and short-term investments; and

     

    • other risks and uncertainties, including those described under Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

     

    Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements or rely on forward-looking statements as predictions of future events. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

     

    Unless the context otherwise indicates, references in this Quarterly Report on Form 10-Q to the terms, “Contineum,” the “Company,” “we,” “our,” and “us” refer to Contineum Therapeutics, Inc. and references to our “common stock” refer to our voting Class A common stock.

     

     

    Table of Contents

     

     

     

     

    CONTINEUM THERAPEUTICS, INC.

     

    TABLE OF CONTENTS

     

       

    Page

    PART I.

    FINANCIAL INFORMATION

     
         

    Item 1.

    Condensed Financial Statements (Unaudited)

    1

     

    Condensed Balance Sheets

    1

     

    Condensed Statements of Operations and Comprehensive Loss

    2

     

    Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

    3

     

    Condensed Statements of Cash Flows

    4

     

    Notes to Unaudited Condensed Financial Statements

    5

    Item 2.

    Management’s Discussion and Analysis of Financial Condition and Results of Operations

    13

    Item 3.

    Quantitative and Qualitative Disclosures About Market Risk

    20

    Item 4.

    Controls and Procedures

    20

         

    PART II.

    OTHER INFORMATION

     
         

    Item 1.

    Legal Proceedings

    21

    Item 1A.

    Risk Factors

    21

    Item 2.

    Unregistered Sales of Equity Securities and Use of Proceeds

    22

    Item 3.

    Defaults Upon Senior Securities

    22

    Item 4.

    Mine Safety Disclosures

    22

    Item 5.

    Other Information

    22

    Item 6.

    Exhibits

    23

    Signatures

    25

     

     

    Table of Contents

     

     

    PART I — FINANCIAL INFORMATION

     

    Item 1. Financial Statements.

     

     

    CONTINEUM THERAPEUTICS, INC.

    CONDENSED BALANCE SHEETS

    (unaudited)

    (in thousands, except share and par value data)

     

      

    March 31, 2025

      

    December 31, 2024

     

    Assets

            

    Current assets:

            

    Cash and cash equivalents

     $22,470  $21,943 

    Marketable securities

      168,240   182,817 

    Prepaid expenses and other current assets

      1,424   1,628 

    Total current assets

      192,134   206,388 

    Property and equipment, net

      891   989 

    Other long-term assets

      4   3 

    Operating lease right-of-use assets

      5,235   5,467 

    Total assets

     $198,264  $212,847 

    Liabilities and Stockholders' Equity

            

    Current liabilities:

            

    Accounts payable

     $3,645  $1,811 

    Accrued expenses

      3,849   6,711 

    Current portion of operating lease liabilities

      1,455   1,452 

    Total current liabilities

      8,949   9,974 

    Operating lease liabilities, net of current portion

      4,547   4,807 

    Total liabilities

      13,496   14,781 

    Commitments and contingencies (Note 8)

              

    Stockholders' equity:

            

    Class A common stock, $0.001 par value; authorized shares—200,000,000 at March 31, 2025 and December 31, 2024; issued and outstanding shares—19,142,377 and 19,125,377 at March 31, 2025 and December 31, 2024, respectively.

      19   19 

    Class B common stock, $0.001 par value; authorized shares—20,000,000 at March 31, 2025 and December 31, 2024; issued and outstanding shares—6,729,172 at March 31, 2025 and December 31, 2024.

      7   7 

    Preferred stock, $0.001 par value; authorized shares—10,000,000 at March 31, 2025 and December 31, 2024; no shares issued or outstanding at March 31, 2025 and December 31, 2024.

      —   — 

    Additional paid-in-capital

      317,964   315,371 

    Accumulated deficit

      (133,392)  (117,402)

    Accumulated other comprehensive income

      170   71 

    Total stockholders' equity

      184,768   198,066 

    Total liabilities and stockholders' equity

     $198,264  $212,847 

     

    The accompanying notes are an integral part of these unaudited condensed financial statements.

     

     

    1

    Table of Contents

     

     

    CONTINEUM THERAPEUTICS, INC.

    CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (unaudited)

    (in thousands, except share and per share data)

     

      

    Three Months Ended March 31,

     
      

    2025

      

    2024

     

    Operating expenses:

            

    Research and development

     $13,712  $7,778 

    General and administrative

      4,398   2,152 

    Total operating expenses

      18,110   9,930 

    Loss from operations

      (18,110)  (9,930)

    Other income (expense):

            

    Interest income

      2,250   1,636 

    Change in fair value of warrant liability

      —   (117)

    Other expense, net

      (130)  (6)

    Total other income, net

      2,120   1,513 

    Net loss

     $(15,990) $(8,417)

    Other comprehensive income (loss):

            

    Unrealized gain (loss) on marketable securities

      99   (166)

    Comprehensive loss

     $(15,891) $(8,583)

    Net loss per share, basic and diluted (a)

     $(0.62) $(3.55)

    Weighted-average shares of common stock outstanding, basic and diluted

      25,868,935   2,369,067 

    _____________

    (a)

    Basic and diluted per share amounts are the same for Class A and Class B shares.

     

    The accompanying notes are an integral part of these unaudited condensed financial statements.

     

    2

    Table of Contents
     

     

    CONTINEUM THERAPEUTICS, INC.

    CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

    (unaudited)

    (in thousands, except share data)

     

      

    Class A and Class B

      

    Additional

      

    Accumulated Other

          

    Total

     
      

    Common Stock

      

    Paid-in

      

    Comprehensive

      

    Accumulated

      

    Stockholders'

     
      

    Shares

      

    Amount

      

    Capital

      

    Income

      

    Deficit

      

    Equity

     

    Balance at December 31, 2024

      25,854,549  $26  $315,371  $71  $(117,402) $198,066 

    Exercise of stock options

      17,000   —   24   —   —   24 

    Stock-based compensation

      —   —   2,569   —   —   2,569 

    Net loss

      —   —   —   —   (15,990)  (15,990)

    Unrealized gain on marketable securities

      —   —   —   99   —   99 

    Balance at March 31, 2025

      25,871,549  $26  $317,964  $170  $(133,392) $184,768 

     

       Convertible    Class A   Additional   Accumulated Other Comprehensive       Total 
      

    Preferred Stock

      

    Common Stock

      

    Paid-in

      

    Income

      

    Accumulated

      

    Stockholders'

     
      

    Shares

      

    Amount

      

    Shares

      

    Amount

      

    Capital

      

    (Loss)

      

    Deficit

      

    Deficit

     

    Balance at December 31, 2023

      15,906,236  $192,620   2,349,554  $2  $7,098  $108  $(75,144) $(67,936)

    Exercise of stock options

      —   —   34,872   —   122   —   —   122 

    Stock-based compensation

      —   —   —   —   768   —   —   768 

    Net loss

      —   —   —   —   —   —   (8,417)  (8,417)

    Unrealized loss on marketable securities

      —   —   —   —   —   (166)  —   (166)

    Balance at March 31, 2024

      15,906,236  $192,620   2,384,426  $2  $7,988  $(58) $(83,561) $(75,629)

     

    The accompanying notes are an integral part of these unaudited condensed financial statements.

    3

    Table of Contents
     

     

    CONTINEUM THERAPEUTICS, INC.

    CONDENSED STATEMENTS OF CASH FLOWS

    (unaudited)

    (in thousands)

     

      

    Three Months Ended March 31,

     
      

    2025

      

    2024

     

    Operating activities

            

    Net loss

     $(15,990) $(8,417)

    Adjustments to reconcile net loss to cash used in operating activities:

            

    Depreciation and amortization

      78   61 

    Non-cash operating lease expense

      233   244 

    Stock-based compensation

      2,569   768 

    Accretion of premiums/discounts on marketable securities, net

      (285)  (1,023)

    Change in fair value of warrant liability

      —   117 
    Gain on marketable securities  (2)  — 

    Loss on disposal of property and equipment

      67   — 

    Changes in operating assets and liabilities

            

    Prepaid expenses and other current assets

      203   713 

    Accounts payable

      1,834   (70)

    Accrued expenses

      (2,862)  (380)

    Operating lease liabilities

      (257)  12 

    Net cash used in operating activities

      (14,412)  (7,975)

    Investing activities

            

    Purchase of property and equipment

      (47)  (147)

    Purchases of marketable securities

      (33,691)  (30,640)

    Sales and maturities of marketable securities

      48,653   39,518 

    Net cash provided by investing activities

      14,915   8,731 

    Financing activities

            

    Payments of deferred offering costs

      —   (140)

    Proceeds from exercise of stock options

      24   122 

    Net cash provided by (used in) financing activities

      24   (18)

    Net increase in cash and cash equivalents

      527   738 

    Cash and cash equivalents at beginning of period

      21,943   15,526 

    Cash and cash equivalents at end of period

     $22,470  $16,264 

     

    The accompanying notes are an integral part of these unaudited condensed financial statements.

     

    4

    Table of Contents

     

    CONTINEUM THERAPEUTICS, INC.

    NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

     

     

    1. Organization and Basis of Presentation

     

    Organization and Nature of Operations

     

    Contineum Therapeutics, Inc. (the “Company”), is a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. The Company was incorporated in the state of Delaware in 2009, and in November 2023 changed its name from Pipeline Therapeutics, Inc. to Contineum Therapeutics, Inc.

     

    Reverse Stock Split

     

    On April 1, 2024, the Company filed an amendment to its fourth amended and restated certificate of incorporation as amended and effected a 1-for-5.5972 reverse stock split of its capital stock. All share and per-share amounts presented in the financial statements and related notes have been retroactively adjusted to reflect the reverse stock split as of the beginning of the first period presented.

     

    Initial Public Offering

     

    On April 9, 2024, the Company closed its initial public offering (the “IPO”), pursuant to which it issued and sold an aggregate of 6,875,000 shares of its common stock at a public offering price of $16.00 per share and on April 19, 2024, the Company issued and sold 548,682 additional shares of its common stock to the underwriters of the IPO pursuant to the partial exercise of their option to purchase additional shares, resulting in net proceeds of approximately $107.9 million, after deducting underwriting discounts, commissions and other offering expenses. Upon the closing of the IPO, the Company’s outstanding convertible preferred stock automatically converted into Class A common stock or Class B common stock, as applicable. Converted redeemable convertible preferred stock outstanding as of the date of the IPO consisted of 15,906,236 shares that were outstanding immediately prior to the closing of the IPO. Following the closing of the IPO, no shares of redeemable convertible preferred stock were authorized or outstanding.

     

    In connection with the closing of the IPO, on April 9, 2024, the Company’s certificate of incorporation was amended and restated to (i) authorize 220,000,000 shares of common stock of which 200,000,000 are designated as Class A common stock and 20,000,000 of which are designated as Class B common stock; (ii) eliminate all references to the previously existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors in one or more series.

     

    Liquidity and Capital Resources

     

    Since its inception, the Company has devoted substantially all its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital to support and expand such activities and providing general and administrative support for these operations. The Company incurred a net loss of $16.0 million for the three months ended March 31, 2025. The Company had an accumulated deficit of $133.4 million as of March 31, 2025. From its inception through March 31, 2025, the Company has financed its operations primarily through issuance of convertible promissory notes, convertible preferred stock financings, a term loan, a global license and development agreement (the “J&J License Agreement”) the Company entered in February 2023 with Janssen Pharmaceutica NV, a Johnson & Johnson company, and net proceeds of approximately $107.9 million received in April 2024 from the IPO.

     

    As of March 31, 2025, the Company had cash, cash equivalents and marketable securities of $190.7 million. Management believes the Company's existing cash, cash equivalents and marketable securities will be sufficient to support its operations for at least 12 months from the issuance date of these unaudited condensed financial statements.

     

    As the Company continues to pursue its business plan, it expects to finance its operations through both public and private sales of equity, debt financings or other commercial arrangements, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties. However, there can be no assurance that any additional financing or strategic transactions will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it may need to delay, reduce or eliminate its product development or future commercialization efforts, which could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Further, if the Company raises funds through licensing or other similar arrangements with third parties, it may be required to relinquish valuable rights to its technology, future revenue streams, research programs or drug candidates or may be required to grant licenses on terms that may not be favorable to it and/or may reduce the value of its common stock.

     

    Unaudited Interim Condensed Financial Statements

     

    The condensed balance sheet as of March 31, 2025, condensed statements of operations and comprehensive loss, condensed statements of convertible preferred stock and stockholders’ equity (deficit), and condensed statements of cash flows for the three months ended March 31, 2025 and 2024, and related notes to condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company’s financial position, results of operations and cash flows for the periods presented. The condensed results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed balance sheet as of  December 31, 2024 included herein was derived from the audited financial statements as of that date. These interim unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 6, 2025. 

     

    5

    Table of Contents
     
     

    2. Summary of Significant Accounting Policies

     

    During the three months ended March 31, 2025, there were no significant changes to the Company's significant accounting policies as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 6, 2025.

     

    Basis of Presentation

     

    The Company has prepared the accompanying condensed financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial statements are presented in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).

     

    Use of Estimates

     

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s financial statements and accompanying notes. Accounting estimates and management judgments reflected in the financial statements include: the accrual of research and development expenses; the incremental borrowing rate used to recognize the right-of-use assets and lease liabilities, the fair value of common stock and convertible preferred stock; and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it  may undertake in the future, actual results  may materially differ from these estimates and assumptions.

     

    Recently Adopted Accounting Pronouncements

     

    In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). This standard requires a public entity to disclose significant segment expenses and other segment items on an interim and annual basis. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A public entity should apply the amendments in this ASU retrospectively to all prior periods presented in the financial statements. The Company adopted ASU 2023-07 for the fiscal year ended  December 31, 2024 and interim financial statements thereafter, on a retrospective basis for all prior periods presented in the financial statements. The adoption of ASU 2023-07 did not change the way that the Company identifies its reportable segments and, as a result, did not have a material impact on the Company’s financial position or results of operations. See Note 10 - Segment Reporting for further information.

     

    Recently Issued Accounting Pronouncements Not Yet Adopted 

     

    In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). This standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements.

     

    In  November 2024, the FASB issued ASU No. 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). This standard requires a public entity to disaggregate certain income statement expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements.

     

    3. Marketable Securities

     

    The Company invests its excess cash in marketable securities, including debt securities, commercial paper, asset-backed securities, yankee debt, certificate of deposit, and U.S. Government agency securities.

     

    The following table summarizes the amortized cost and fair value of the Company’s marketable securities by major investment category (in thousands):

       

    March 31, 2025

     
           

    Unrealized

         
     

    Maturity in Years

     

    Amortized Cost

      

    Gains

      

    Losses

      

    Fair Value

     

    U.S. Government agency securities

    3 years or less

     $56,647  $88  $(35) $56,700 

    Certificate of deposit

    Less than 1

      6,661   5   —   6,666 

    Corporate debt securities

    2 years or less

      71,776   78   (14)  71,840 

    Commercial paper

    Less than 1

      14,664   5   (1)  14,668 

    Yankee debt

    Less than 1

      2,923   1   —   2,924 

    Asset-backed securities

    4 years or less

      15,396   46   —   15,442 
    Total  $168,067  $223  $(50) $168,240 

     

       

    December 31, 2024

     
           

    Unrealized

         
     

    Maturity in Years

     

    Amortized Cost

      

    Gains

      

    Losses

      

    Fair Value

     

    U.S. Government agency securities

    3 years or less

     $57,232  $57  $(134) $57,155 

    Certificate of deposit

    Less than 1

      8,519   6   (1)  8,524 

    Corporate debt securities

    2 years or less

      80,751   110   (39)  80,822 

    Commercial paper

    Less than 1

      22,265   11   (1)  22,275 

    Yankee debt

    Less than 1

      2,145   1   —   2,146 

    Asset-backed securities

    2 years or less

      11,834   61   —   11,895 
    Total  $182,746  $246  $(175) $182,817 

     

    The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, current and expected future economic conditions. The Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. As of March 31, 2025 and December 31, 2024, the Company did not record an allowance for credit loss related to its investment portfolio. As of March 31, 2025, 60 out of 243 of our available-for-sale debt securities were in an aggregate gross unrealized loss position. As of  December 31, 2024, 86 out of 252 of our available-for-sale debt securities were in an aggregate gross unrealized loss position. As of March 31, 2025 and December 31, 2024, all of our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded had continuous unrealized loss positions of less than 12 months.

     

    The following tables summarize our available-for-sale debt securities in an unrealized loss position for which an allowance for credit losses has not been recorded, aggregated by major security type (in thousands):

     

      March 31, 2025 
      Fair Value  Unrealized Losses 
    U.S. Government agency securities $13,803  $(35)
    Corporate debt securities  22,271   (14)
    Commercial paper  8,414   (1)
    Total $44,488  $(50)

     

     

      December 31, 2024 
      Fair Value  Unrealized Losses 
    U.S. Government agency securities $30,155  $(134)
    Certificate of deposit  3,722   (1)
    Corporate debt securities  22,528   (39)
    Commercial paper  4,556   (1)
    Total $60,961  $(175)

     

     

    6

    Table of Contents
     
     

    4. Fair Value Measurements

     

    The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

     

    Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

     

    Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

     

    Level 3—Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

     

    Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):

     

          

    Fair Value Measurements Using

     
          Quoted Prices in  Significant Other  Significant 
          

    Active Markets

      

    Observable

      

    Unobservable

     
          

    for Identical

      

    Inputs

      

    Inputs

     
      

    Total

      

    Assets (Level 1)

      

    (Level 2)

      

    (Level 3)

     

    As of March 31, 2025:

                    

    Assets:

                    

    Cash equivalents

     $20,446  $20,446  $—  $— 

    U.S. Government agency securities

      56,700   56,700   —   — 

    Certificates of deposits

      6,666   —   6,666   — 

    Corporate debt securities

      71,840   —   71,840   — 

    Commercial paper

      14,668   —   14,668   — 

    Yankee debt

      2,924   —   2,924   — 

    Asset-backed securities

      15,442   —   15,442   — 

    Total financial assets

     $188,686  $77,146  $111,540  $— 
                     

    As of December 31, 2024:

                    

    Cash equivalents

     $21,042  $21,042  $—  $— 

    U.S. Government agency securities

      57,155   57,155   —   — 

    Certificates of deposits

      8,524   —   8,524   — 

    Corporate debt securities

      80,822   —   80,822   — 

    Commercial paper

      22,275   —   22,275   — 

    Yankee debt

      2,146   —   2,146   — 

    Asset-backed securities

      11,895   —   11,895   — 

    Total financial assets

     $203,859  $78,197  $125,662  $— 

     

    The carrying amounts of the Company’s financial instruments, including cash, cash equivalents and marketable securities, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Included in cash and cash equivalents at March 31, 2025 and December 31, 2024 are money market funds with a carrying value and fair value of $5.0 million and $3.9 million, respectively, based upon a Level 1 fair value assessment.

    7

    Table of Contents

     

     

    5. Accrued Expenses

     

    Accrued expenses consisted of the following (in thousands):

     

      

    March 31,

      

    December 31,

     
      

    2025

      

    2024

     

    Accrued compensation expenses

     $1,192  $3,338 

    Accrued research and development expenses

      2,479   3,151 

    Accrued professional and consulting expenses

      116   98 

    Other accrued expenses

      62   124 

    Total accrued expenses

     $3,849  $6,711 

     

     

    6. Stockholders’ Equity (Deficit)

     

    Common Stock

     

    The Company has two classes of common stock: Class A common stock and Class B common stock. Class A common stock has one vote per share and Class B common stock has no votes per share. As of March 31, 2025, of the authorized 200,000,000 shares of Class A common stock, 19,142,377 shares of Class A common stock were issued and outstanding, and of the authorized 20,000,000 shares of Class B common stock, 6,729,172 shares of Class B common stock were issued and outstanding.

     

    Class A common stock reserved for future issuance consisted of the following:

     

    8

    Table of Contents
     
      

    March 31,

      

    December 31,

     
      

    2025

      

    2024

     

    Common stock options granted and outstanding

      5,107,770   4,045,500 

    Shares available for issuance under the 2024 Equity Incentive Plan

      1,887,766   1,674,309 

    Common stock warrant

      15,764   15,764 

    Common stock reserved under the 2024 Employee Stock Purchase Plan

      520,549   262,004 

    Total common stock reserved for future issuance

      7,531,849   5,997,577 

     

     There are no shares of Class B common stock reserved for future issuance as of March 31, 2025 and December 31, 2024.

     

    9

    Table of Contents
     

    Stock Options

     

    In March 2024, the Company's board of directors and its stockholders adopted and approved the 2024 Equity Incentive Plan (the “2024 Plan”). The 2024 Plan is the successor of the Company's 2012 Equity Incentive Plan (the “2012 Plan”). However, awards outstanding under the 2012 Plan will continue to be governed by their existing terms. The 2024 Plan allowed for the issuance of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted shares, restricted stock units, and other stock awards to the Company's employees, members of its board of directors, and consultants. 

     

    The number of shares initially reserved for issuance under the 2024 Plan was 2,700,000. As of March 31, 2025, there were 1,887,766 shares of the Company’s Class A common stock available for issuance under the 2024 Plan. The aggregate number of shares reserved for issuance under the 2024 Plan will automatically increase on the first day of each fiscal year of the Company, commencing in 2025 and ending in (and including) 2034, by a number equal to the lesser of (a) 5% of the aggregate shares of Class A common stock and Class B common stock issued and outstanding as of the last day of the prior fiscal year, or (b) a number of shares of Class A common stock determined by the Company's board of directors.

     

    Under the 2024 Plan, the exercise price for options granted under the 2024 Plan may not be less than 100% of the fair market value of the Class A common stock on the grant date. Optionees will be permitted to pay the exercise price in cash or, with the consent of the compensation committee (i) with shares of common stock that the optionee already owns, (ii) by an immediate sale of shares through a broker approved by the Company, (iii) by instructing the Company to withhold a number of shares otherwise deliverable upon exercise having an aggregate fair market value that does not exceed the exercise price, or (iv) by other methods permitted by applicable law.  

     

    The Company's board of directors (or a committee thereof to which the Company's board of directors has delegated authority) may amend or terminate the 2024 Plan at any time. If the Company's board of directors amends the 2024 Plan, it does not need stockholder approval of the amendment unless required by applicable law, regulation or rules. The 2024 Plan will terminate automatically ten years after the date when the Company's board of directors adopted the 2024 Plan.

     

    Stock option activity under the 2024 Plan and 2012 Plan is as follows:

     

      

    Options Outstanding

      

    Weighted- Average Exercise Price

      

    Weighted- Average Remaining Contractual Term

      

    Aggregate Intrinsic Value (in thousands)

     

    Balance at December 31, 2024

      4,045,500  $9.91   7.52  $21,470 

    Options granted

      1,081,744   9.79   —   — 

    Options exercised

      (17,000)  1.41   —   — 

    Options cancelled and forfeited

      (2,474)  12.42   —   — 

    Options expired

      —   —   —   — 

    Balance at March 31, 2025

      5,107,770  $9.91   7.82  $5,910 

    Options Vested and Expected to Vest as of March 31, 2025

      5,107,770  $9.91   7.82  $5,910 

    Options Exercisable as of March 31, 2025

      2,212,484  $5.78   5.86  $5,901 

     

    The aggregate intrinsic value of options exercised during the three months ended  March 31, 2025 and 2024 was $0.2 million and $0.3 million, respectively, determined as of the date of exercise. Options exercisable include options which are not vested but are available to be early exercised. As of March 31, 2025, of the 2,212,484 options exercisable, 112 options are available to be early exercised. As of  December 31, 2024, of the 2,114,772 options exercisable, 35,794 options are available to be early exercised.

     

    10

    Table of Contents
     

    The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for any forfeitures of options when they occur. Previously recognized compensation expense for an award is reversed in the period that the award is forfeited. The fair value of stock options was estimated using the following weighted-average assumptions:

     

      

    Three Months Ended March 31,

     
      

    2025

      

    2024

     

    Assumptions:

            

    Expected term (in years)

      6.07   5.94 

    Expected volatility

      93%  111%

    Risk free interest rate

      4.41%  4.18%

    Dividend yield

      —   — 

     

    The weighted-average grant-date fair value per share of stock options granted during the three months ended March 31, 2025 and 2024 was $7.64 and $13.66 per share, respectively.

     

    The Company recorded $1.5 million and $1.1 million in stock-based compensation in general and administrative and research and development, respectively, for the three months ended March 31, 2025. The Company recorded $0.4 million and $0.4 million in stock-based compensation in general and administrative and research and development, respectively, for the three months ended March 31, 2024.

     

    As of March 31, 2025, there was approximately $26.3 million of total unrecognized stock-based compensation related to nonvested stock-based compensation arrangements, which is expected to be recognized over a weighted-average period of approximately 3.1 years. As of March 31, 2024, there was approximately $9.2 million of total unrecognized stock-based compensation related to nonvested stock-based compensation arrangements, which was expected to be recognized over a weighted-average period of approximately 1.3 years.

     

    Employee Stock Purchase Plan

     

    In March 2024, the Company's board of directors and its stockholders adopted and approved the 2024 Employee Stock Purchase Plan (the “2024 ESPP”). The 2024 ESPP became effective as of  April 9, 2024. The purpose of the 2024 ESPP is to provide eligible employees with an opportunity to increase their interest in the success of the Company by purchasing shares of Class A common stock from the Company on favorable terms and to pay for such purchases through payroll deductions or other approved contributions. The new payroll deduction rate may be any whole percentage of the participant’s compensation, but not less than 1% nor more than 15%.

     

    The number of shares initially reserved for issuance under the 2024 ESPP was 280,000. As of March 31, 2025, there were 520,549 shares of the Company’s common stock reserved and available for issuance under the 2024 ESPP. The number of shares reserved for issuance under the 2024 ESPP will automatically increase on the first day of each fiscal year of the Company, commencing in 2025 and ending in (and including) 2044, by a number equal to the lesser of (i) 280,000 shares, (ii) 1% of the aggregate shares of Class A common stock and Class B common stock issued and outstanding on the last day of the prior fiscal year, or (iii) a number of shares determined by the Company's board of directors. The number of shares reserved under the 2024 ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit). 

     

    During the three months ended March 31, 2025, there were no shares purchased under the 2024 ESPP and the recorded expense was not material.

     

    7. License Agreement

     

    In February 2023, the Company entered into the J&J License Agreement, pursuant to which the Company granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications. The J&J License Agreement allows the Company to elect, at its sole discretion and cost, to conduct a Phase 2 trial of PIPE-307 for patients with multiple sclerosis. After such trial, J&J may, at its sole discretion, further develop PIPE-307 for patients with multiple sclerosis. Additionally, upon J&J deciding to conduct a first Phase 3 clinical trial for a product using PIPE-307, the J&J License Agreement allows the Company the option to co-fund a portion of all Phase 3 and subsequent development costs for PIPE-307, with such costs capped annually. If the Company opts to fund such development costs, then the royalties the Company is eligible to receive will increase. Pursuant to the terms of the J&J License Agreement, the Company received an upfront, non-refundable and non-creditable payment of $50.0 million upon transferring the license and know-how, existing inventory and manufacturing technology. The Company is also eligible to receive approximately $1.0 billion in non-refundable, non-creditable milestone payments. Additionally, the Company is eligible to receive tiered royalties in the low-double digit to high-teen percent range on net sales of products containing PIPE-307.

     

    The Company sold approximately 1.7 million shares of series C convertible preferred stock to Johnson & Johnson Innovation - JJDC, Inc., an affiliate of J&J, at $15.00 per share, for an aggregate purchase price of approximately $25.0 million, in April 2023. The Company determined that this preferred stock purchase was at fair value as other new investors purchased shares of preferred stock at the same price.

     

    The Company concluded that J&J represented a customer and applied relevant guidance from ASC 606 to evaluate the appropriate accounting for the J&J License Agreement. The Company evaluated the J&J License Agreement and concluded that it had promises to transfer a license of functional intellectual property, know-how, existing inventory and manufacturing technology (each of which was determined to be a distinct performance obligation). Control of the promised goods was transferred to J&J in the second quarter of 2023, and the $50.0 million upfront payment was recognized in May 2023 upon satisfaction of the performance obligations. The remaining consideration consists of future contingent milestone-based payments and sales-based royalties. As of March 31, 2025, all variable consideration under the J&J License Agreement was fully constrained.

     

    In August 2023, the Company elected to conduct a Phase 2 trial using PIPE-307 for patients with multiple sclerosis, which was considered a contract modification under the accounting guidance that added promised goods or services that are distinct at a price that is below the standalone selling price. Therefore, the Company accounted for the modification as a termination of the existing contract and creation of a new contract. Accordingly, the amount of consideration to be allocated to the remaining performance obligations consists of future contingent milestone-based payments and sales-based royalties, all of which were constrained. The only remaining performance obligation is the promise to conduct the Phase 2 trial, as the other performance obligations had been satisfied prior to the modification date. Accordingly, the variable consideration allocated to the Phase 2 trial will be recognized as the study is completed using a cost-based measure of progress and when the amounts are no longer probable of a significant reversal. As of March 31, 2025, no amounts had been recognized related to the Phase 2 trial as no additional variable consideration has been received subsequent to the contract modification.

     

    8. Commitments and Contingencies 

     

    Operating Lease

     

    The Company leases office and lab space in San Diego, California under a non-cancelable operating lease (“Science Center Drive Lease”). The lease commenced in  March 2018 and has a 5-year initial term. The lease includes a renewal option, which includes an option to renew for five additional years. During 2021, the Company amended the lease to include additional space in the building with the right to use the new space beginning in  October 2021, for an additional 3 years.

     

    In  October 2023, the Company executed a noncancelable operating lease for new premises to be used for office, research and development and laboratory purposes (“General Atomics Court Lease”), with the same landlord as the Science Center Drive Lease. The General Atomics Court Lease commenced for accounting purposes in  October 2024 when the Company took control of the premises and has a 5-year initial term from the commencement date. The General Atomics Court Lease has a five-year term with an option to extend for another three-year period subject to certain conditions, which the Company is not reasonably certain to exercise and therefore was not considered in determining the right-of-use (“ROU”) assets and lease liabilities balance. 

     

    As a result of the new lease, the Company received rent abatement from  January to  October 2024 on the Science Center Drive Lease. This resulted in a modification of the Science Center Drive Lease and a remeasurement of the existing lease liability and the associated right-of-use asset in  October 2023. As a result, $0.6 million from the payments of the new lease were allocated to the Science Center Drive Lease, based on a relative standalone selling price analysis. 

     

    The Company’s operating lease ROU asset and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. Upon commencement of the new lease, in  October 2024, the Company recorded an ROU asset and lease liability of approximately $5.6 million. This includes the $0.6 million allocation, which led to a corresponding decrease in the ROU asset value for the new lease. The lease agreement includes variable payments which are not included in the measurement of the ROU assets and lease liability. 

     

    Below is a summary of the Company’s operating lease right-of-use assets and lease liabilities (in thousands, except for years and %):

      March 31,   December 31, 
      2025  2024 
    Operating lease right-of-use assets $5,235  $5,467 
             
    Operating lease liability obligations, current $1,455  $1,452 
    Operating lease liability obligations, less current portion  4,547   4,807 
    Total lease liability obligations $6,002  $6,259 
             
    Weighted-average remaining lease term  4.5   4.4 
    Weighted-average discount rate  9.0%  9.0%

     

    During the three months ended  March 31, 2025 and 2024, the Company recognized $0.4 million and $0.3 million, respectively, in operating lease expenses, which are included in operating expenses in the Company's statements of operations and comprehensive loss.

     

    Supplemental cash flow information related to operating leases are as follows (in thousands):

       March 31,   March 31,  
      2025  2024 
    Cash paid for amounts included in the measurement of lease liabilities $378  $— 

     

    Future minimum lease payments for the Company’s operating lease liabilities as of March 31, 2025 are as follows (in thousands):

     

    2025 $1,141
    2026  1,564
    2027  1,611
    2028  1,660
    2029  1,292
    Total minimum lease payments  7,268
    Less: amount representing interest  1,266
    Total lease liability obligations  6,002
    Less: Current portion of operating lease liabilities  1,455
    Operating lease liabilities, net of current portion $4,547

     

    Litigation

     

    From time to time, the Company  may become involved in various legal proceedings and claims that arise in the ordinary course of our business activities. As of March 31, 2025, the Company was not currently a party to any material legal proceedings. 

     

    Other Commitments

     

    The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. Such contracts are generally terminable with advanced written notice and payment for any products or services received by the Company through the effective time of termination and any non-cancelable and non-refundable obligations incurred by the vendor at the effective time of the termination. In the case of terminating a clinical trial agreement at a particular site, the Company would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.

     

     

    9. Net Loss Per Share

     

    The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):

     

      

    Three Months Ended March 31,

     
      

    2025

      

    2024

     

    Numerator:

            

    Net loss applicable to common stockholders

     $(15,990) $(8,417)

    Denominator:

            

    Weighted average shares used to compute net loss per common share, basic and diluted

      25,868,935   2,369,067 

    Net loss per share:

            

    Basic and diluted

     $(0.62) $(3.55)

     

    11

    Table of Contents
     

    For the three months ended March 31, 2025, net loss is attributable equally to each share of Class A common stock and Class B common stock and is determined based on the weighted-average number of the respective class of common stock outstanding. Weighted-average common shares include shares of the Company's Class A common stock and Class B common stock. The basic and diluted net loss per share amounts are the same for Class A common stock and Class B common stock.

     

    The Company’s potentially dilutive securities, which include convertible preferred stock, common stock options, a preferred stock warrant, and a common stock warrant have been excluded from the computation of diluted net loss per share for the three months ended March 31, 2025 and 2024, as the effect would reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

     

    The following potentially dilutive securities have been excluded from the diluted per share calculation for the periods presented as they would be anti-dilutive:

     

      

    As of March 31,

      

    As of March 31,

     
      

    2025

      

    2024

     

    Convertible preferred stock (as converted to common stock)

      —   15,906,273 

    Common stock options

      5,107,770   2,881,863 

    Preferred stock warrant (as converted to common stock)

      —   15,764 

    Common stock warrant

      15,764   — 
    Total potentially dilutive securities  

    5,123,534

       

    18,803,900

     

     

     

    10. Segment Reporting

     

    The Company operates in one reportable segment, pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need.

     

    Our chief operating decision maker (“CODM”) is our President and Chief Executive Officer, Carmine Stengone. The CODM uses operating expenses, as reported on our statements of operations and comprehensive loss. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results of the Company as a whole using operating expenses. Net loss is also a measure that is considered in monitoring budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

     

    Significant segment expenses within net loss include research and development related to PIPE-791, PIPE-307, CTX-343, discovery programs and unallocated internal costs, general and administrative and interest income. 

     

    The following table provides the operating financial results of our single reportable segment (in thousands):

     

      Three Months Ended March 31, 
      2025  2024 
    Significant and other segment expenses        
    Research and development        
    PIPE-791 $5,554  $2,861 
    PIPE-307  2,615   2,075 
    CTX-343  1,378   312 
    Discovery programs  1,382   1,104 
    Unallocated internal costs  2,783   1,426 
    General and administrative  4,398   2,152 
    Interest income  2,250   1,636 
    Other segment items (1)  (130)  (123)
    Net loss $(15,990) $(8,417)

    ______________________

    (1)

    Other segment items primarily include change in fair value of warrant liability and other expense, net.

     


     

    12

    Table of Contents
     
     

    Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

     

    The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited financial statements and related notes thereto as of and for the year ended December 31, 2024 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 6, 2025. 

     

    This Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements, which represent our intent, belief, or current expectations, involve risks and uncertainties. We use words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “predict,” “potential,” “believe,” “should” and similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements may include, but are not limited to, statements concerning projections about our accounting and finances, our clinical trial and product development plans and timelines, the indications, anticipated benefits of, and market opportunities for our drug candidates, our operating runway, our business strategies and plans, and other statements regarding future performance. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. As a result of many factors, including without limitation those set forth under “Risk Factors” under Item 1A of Part II below, and elsewhere in this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in these forward-looking statements. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes.

     

    Overview

     

    We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease.

     

    We have focused our efforts on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications. We are developing PIPE-307 in collaboration with J&J.

     

    Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (“LPA1R”) in development for idiopathic pulmonary fibrosis (“IPF”), progressive multiple sclerosis (“PrMS”), and chronic pain. LPA1R antagonism is a clinically validated mechanism in IPF, and we believe that our preclinical studies and Phase 1 healthy volunteer data support the development of PIPE-791 for IPF, as well as PrMS and chronic pain. Specifically, based on its high bioavailability, low plasma protein binding, and long receptor residence time in our preclinical studies compared to the preclinical data of other LPA1R antagonists, we believe PIPE-791 has the potential to be a differentiated LPA1R therapy. We have completed a Phase 1 clinical trial of PIPE-791 in healthy volunteers in support of clinical development in IPF, PrMS and chronic pain. In December 2024, we commenced a Phase 1b open-label trial to measure the relationship of pharmacokinetics to lung and brain receptor occupancy by positron emission tomography (“PET”) imaging. We expect the top-line data from this trial will be available in the second quarter of 2025. This Phase 1b PET trial will inform dose selection for our planned Phase 2 trials of PIPE-791 in IPF and PrMS. On March 4, 2025, we announced the initiation of patient dosing in an exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial for the treatment of chronic pain associated with two separate indications, osteoarthritis and low back pain. We expect to enroll approximately 40 patients at up to five sites in the U.S., and a treatment duration of 28 days. We anticipate top-line data from this trial in early 2026.

     

    Our second drug candidate, PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 receptor (“M1R”), in development for depression and relapse-remitting multiple sclerosis (“RRMS”). We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. In 2023, we initiated a Phase 2 VISTA trial of PIPE-307 for the potential treatment of RRMS. In January 2025, we announced that we have fully enrolled our Phase 2 VISTA trial. We expect the top-line data from this trial will be available in the second half of 2025. In December 2024, J&J began recruiting an estimated 124 adult participants for a Phase 2 trial of PIPE-307/JNJ-89495120 for the potential treatment of major depressive disorder (“MDD”). This trial is a randomized, double-blind, multicenter, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of PIPE-307/JNJ-89495120 as monotherapy in adult participants with MDD. We believe PIPE-307 is the most advanced selective M1R antagonist in clinical development.

     

    In addition, we are leveraging our drug discovery capabilities to expand our clinical portfolio. In January 2024, we nominated and commenced preclinical studies for CTX-343, a peripherally-restricted (unable to access the central nervous system) LPA1R antagonist. In parallel, we are actively conducting preclinical and discovery-phase experiments targeting other NI&I indications where our internally-discovered molecules may have therapeutic potential.

     

    13

    Table of Contents

     

    We have a portfolio of novel and proprietary small molecule programs that we believe can modulate innate pathways to restore function in NI&I indications. We retain worldwide rights to our LPA1R programs and discovery portfolio, and we have partnered with J&J for the development and potential commercialization efforts of PIPE-307. 

     

    pipeline2025.jpg

     

    We expect our operating expenses to significantly increase as we continue to develop, conduct clinical trials, and seek regulatory approvals for our drug candidates, engage in other research and development activities to expand the indications for our existing drug candidates and develop a pipeline of additional drug candidates, expand our operations and headcount, maintain and expand our intellectual property portfolio, and, if we obtain approval for one or more of our drug candidates, launch commercial activities. We also expect to incur additional operating expenses as we continue operating as a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing and scope of our clinical trials and our expenditures on other research and development activities.

     

    As we continue to pursue our business plan, we expect to finance our operations through both public and private sales of equity, debt financings or other commercial arrangements, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties. However, there can be no assurance that any additional financing or strategic transactions will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we may need to delay, reduce or eliminate our product development or future commercialization efforts, which could have a material adverse effect on our business, results of operations or financial condition. Further, if we raise funds through licensing or other commercial arrangements with third parties, we may be required to relinquish valuable rights to our technology, future revenue streams, research programs or drug candidates or may be required to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock.

     

    Collaboration

     

    In February 2023, we entered into a license agreement with J&J (the “J&J License Agreement”), pursuant to which we granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications.

     

    J&J is generally responsible for all development, manufacturing and commercialization activities for PIPE-307. Upon J&J conducting a first Phase 3 clinical trial for a product using PIPE-307, we have an opt-in right to fund a portion of all Phase 3 and subsequent development costs for PIPE-307. If we opt to fund such development costs, then the royalties we are eligible to receive will increase by one to two percentage points.

     

    We are conducting, at our own expense, a Phase 2 clinical trial of PIPE-307 in patients with RRMS. We completed enrollment of our Phase 2 clinical trial in December 2024, and expect the top-line data from this trial will be available in the second half of 2025. J&J has the right to discontinue our clinical trial if it has good faith concerns that this trial presents safety risks or could have a material adverse effect on its development or commercialization of PIPE-307. In addition, J&J has the right, in its sole discretion, to further develop or to elect not to develop PIPE-307 for this indication. In December 2024, J&J began recruiting an estimated 124 adult participants for a Phase 2 trial of PIPE-307/JNJ-89495120 for the potential treatment of MDD. This trial is a randomized, double-blind, multicenter, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of PIPE-307/JNJ-89495120 as monotherapy in adult participants with MDD.

     

    The J&J License Agreement expires on a licensed product-by-product and country-by-country basis upon the last to occur of: (i) the expiration of the last-to-expire licensed patent claim covering the composition of matter of the licensed compound in such licensed product in such country; (ii) the expiration of exclusive marketing rights conferred by a regulatory authority or applicable law (other than patent exclusivity) for such licensed product in such country; or (iii) ten years after the first commercial sale of such licensed product in such country. Either party may terminate the J&J License Agreement in the event of an uncured material breach by the other party or a bankruptcy or insolvency of the other party. J&J may terminate the J&J License Agreement without cause upon prior written notice to us. Upon any termination, all license rights granted to J&J terminate.

     

    14

    Table of Contents

     

    Financial Operations Overview

     

    Revenue

     

    We recognize license revenues as identified performance obligations are satisfied or other events occur, specifically related to our J&J License Agreement. Pursuant to the terms of the J&J License Agreement, we received an upfront payment of $50.0 million in May 2023. We are also eligible to receive approximately $1.0 billion in non-refundable, non-creditable milestone payments, pursuant to the terms of the J&J License Agreement. Additionally, we are eligible to receive tiered royalties in the low-double digit to high-teen percent range on net sales of products containing PIPE-307. We do not have any products approved for sale and we have not yet generated any revenue from product sales. We did not recognize any revenue for the three months ended March 31, 2025 or 2024. 

     

    Operating Expenses

     

    Research and Development

     

    Research and development expenses consist primarily of costs incurred for our internal research and development activities.

     

    Direct costs include:

     

     

    •

    employee-related expenses, including salaries, related benefits, and travel that can be directly attributable to each research project;

     

     

    •

    expenses incurred in connection with research, laboratory consumables and preclinical studies;

     

     

    •

    expenses incurred in connection with conducting clinical trials, including investigator grants and site payments for time and pass-through expenses and expenses incurred under agreements with contract research organizations (“CROs”), other vendors or central laboratories and service providers engaged to conduct our trials;

     

     

    •

    the cost of consultants engaged in research and development related services;

     

     

    •

    the cost to manufacture drug products for use in our preclinical studies and clinical trials; and

     

     

    •

    costs related to regulatory compliance.

     

    Unallocated internal research and development costs include:

     

     

    •

    employee-related expenses, including salaries, related benefits, and travel that cannot be directly attributable to a specific research project;

     

     

    •

    stock-based compensation for employees engaged in research and development functions; and

     

     

    •

    facilities, depreciation and other related expenses.

     

    We expense our research and development costs as they are incurred. We record advance payments for goods or services to be received in the future for use in research and development as prepaid expenses. We then expense the prepaid amounts as the related goods are delivered or the services are performed.

     

    We track outsourced development costs, consultant costs and other external research and development costs such as third-party contract costs relating to manufacturing, clinical trial activities, translational medicine and toxicology activities to specific programs. We allocate employee related costs including salaries and related benefits based upon the level of effort for each specific project.

     

    Certain employee activities that cannot be allocated to any one specific project or management related activities are considered indirect costs. The following tables summarize our research and development expenses for the three months ended March 31, 2025 and 2024. The direct external development program expenses reflect external costs attributable to our clinical development and preclinical programs and personnel costs that can be directly attributed to a development program. The unallocated internal research and development costs include unallocated personnel costs, facility costs, stock-based compensation, laboratory consumables and discovery and research related activities.

     

        Three Months Ended  
        March 31,  
       

    2025

       

    2024

     
        (in thousands)  

    Direct external development program expense

                   

    PIPE-791

      $ 5,554     $ 2,861  

    PIPE-307

        2,615       2,075  

    CTX-343

        1,378       312  

    Discovery programs

        1,382       1,104  

    Unallocated internal research and development costs

                   

    Personnel related

        628       369  

    Stock-based compensation

        1,083       388  

    Facilities costs

        504       219  

    Others

        568       450  

    Total research and development costs

      $ 13,712     $ 7,778  

     

    15

    Table of Contents

     

    Research and development activities are central to our business model. There are numerous factors associated with the successful commercialization of any of our drug candidates, including future clinical trial design and various regulatory requirements, many of which we cannot determine with accuracy at this time based on our stage of development. In addition, future regulatory factors beyond our control may impact our clinical development programs. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our drug candidates and our costs may increase if we exercise our opt-in right to fund a portion of all Phase 3 and subsequent development costs for PIPE-307 pursuant to the J&J License Agreement. However, we expect that our research and development expenses will increase substantially in connection with our planned preclinical and clinical development activities in the near term and for the foreseeable future.

     

    The successful development of our drug candidates is highly uncertain. This is due to numerous risks and uncertainties, including the following:

     

     

    •

    successful completion of preclinical studies and clinical trials;

     

     

    •

    delays in regulators or institutional review boards authorizing us or our investigators to commence or continue our clinical trials;

     

     

    •

    our ability to negotiate agreements with clinical trial sites or CROs;

     

     

    •

    the number of clinical sites included in our clinical trials;

     

     

    •

    raising additional funds necessary to complete clinical development of our drug candidates;

     

     

    •

    obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our drug candidates;

     

     

    •

    establishing and qualifying manufacturing capabilities for clinical supplies of our drug candidates, whether directly or through qualified third party manufacturers;

     

     

    •

    our ability to receive necessary regulatory approvals from the U.S. Food and Drug Administration and comparable governmental bodies outside the United States;

     

     

    •

    our decision to elect to fund a portion of Phase 3 and subsequent development costs for PIPE-307; 

     

     

    •

    coverage for our products by governmental and third party payors;

     

     

    •

    protecting and enforcing our rights in our intellectual property portfolio;

     

     

    •

    our ability to successfully compete with our competitors and their product offerings; and

     

     

    •

    maintaining a continued acceptable safety profile of the products following approval.

     

    A change in the outcome of any of these variables with respect to the development of our drug candidates may significantly impact the costs and timing associated with the development of our drug candidates. We may never succeed in obtaining regulatory approval for any of our drug candidates or successfully commercialize our products, even if approved.

     

    General and Administrative

     

    General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include legal fees relating to intellectual property, patent applications, and corporate matters, professional fees for accounting and consulting services and facility-related costs.

     

    We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities, the growth of our business operations and headcount and to reflect increased operating expenses as we continue operating as a public company. These increased costs will likely include increased expenses related to audit, legal, regulatory services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs.

     

    Other Income (Expense)

     

    Interest Income

     

    Interest income consists of interest earned on our cash, cash equivalents and marketable securities.

     

    16

    Table of Contents

     

    Results of Operations

     

    Comparison of the Three Months Ended March 31, 2025 and 2024

     

    The following table summarizes our results of operations (in thousands) for the periods indicated:

     

        Three Months Ended          
        March 31,          
       

    2025

       

    2024

       

    Change

     

    Operating expenses:

                           

    Research and development

      $ 13,712     $ 7,778     $ 5,934  

    General and administrative

        4,398       2,152       2,246  

    Total operating expenses

        18,110       9,930       8,180  

    Loss from operations

        (18,110 )     (9,930 )     (8,180 )

    Other income (expense):

                           

    Interest income

        2,250       1,636       614  

    Change in fair value of warrant liability

        —       (117 )     117  

    Other expense, net

        (130 )     (6 )     (124 )

    Total other income, net

        2,120       1,513       607  

    Net loss

      $ (15,990 )   $ (8,417 )   $ (7,573 )

     

    Research and development expenses. Research and development expenses were $13.7 million and $7.8 million for the three months ended March 31, 2025 and 2024, respectively. The increase of $5.9 million from period to period was due to the following:

     

     

    •

    $3.8 million increase in contract research organization costs primarily related to our ongoing VISTA Phase 2 clinical trial for PIPE-307 for the potential treatment of RRMS, Phase 1b trial for PIPE-791 for the treatment of chronic pain, and Phase 1b PET trial for PIPE-791,

     

     

    •

    $0.8 million increase in personnel-related expense related to an overall increase in personnel from period to period,

     

     

    •

    $0.7 million increase in non-cash stock-based compensation,

     

     

    •

    $0.3 million increase in facilities costs,

     

     

    •

    $0.2 million increase in biology and chemistry supplies, and

     

     

    •

    $0.1 million increase in expenses for toxicology studies primarily for PIPE-791.

     

    General and administrative expenses. General and administrative expenses were $4.4 million and $2.2 million for the three months ended March 31, 2025 and 2024, respectively. The increase of $2.2 million was due to a $1.1 million increase in non-cash stock-based compensation, a $0.7 million increase in personnel-related expenses related to an overall increase in personnel from period to period, a $0.2 million increase in director and officer insurance associated with our recently completed IPO, and a $0.1 million increase in facilities costs.

     

    Interest income. Interest income was $2.3 million and $1.6 million for the three months ended March 31, 2025 and 2024, respectively. The increase of $0.6 million was due to an increase in funds invested in marketable securities.

     

    Liquidity and Capital Resources

     

    Sources of Liquidity

     

    We have incurred net losses and negative cash flows from operations in nearly every reporting period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. We expect to incur substantial expenditures as we advance our drug candidates through clinical development, undergo the regulatory approval process, engage in other research and development activities to expand our pipeline of drug candidates, expand our operations and headcount, maintain and expand our intellectual property portfolio and, if we obtain approval for one or more of our drug candidates, launch commercial activities. We also expect to incur additional costs associated with our operating as a public company, including significant legal, accounting, investor relations, director and officer insurance, and other expenses that we did not incur as a private company.

     

    Through March 31, 2025, we have funded our operations primarily through the issuance of convertible promissory notes, private placements of our convertible preferred stock, the J&J License Agreement, and net proceeds from the IPO. Through March 31, 2025, we have raised gross proceeds of approximately $312.8 million from the issuance of our convertible preferred stock, promissory notes, and Class A common stock in our IPO. In addition, we received an upfront payment from the J&J License Agreement of $50.0 million and borrowed $5.0 million at the inception of the loan and security agreement with First Citizens Bank. Upon the closing of the IPO, our outstanding convertible preferred stock automatically converted into Class A common stock or Class B common stock, as applicable. In April 2024, we raised approximately $107.9 million in net proceeds from the IPO. As of March 31, 2025, we had an accumulated deficit of $133.4 million.

     

    As of March 31, 2025, we had cash, cash equivalents and marketable securities of $190.7 million. Based on our current operating plan, we believe that our existing cash and cash equivalents and short-term investments, will be sufficient to meet our anticipated operating expenses and capital expenditure requirements through at least the next 12 months, following the date of this Quarterly Report on Form 10-Q.

     

    17

    Table of Contents

     

    As we continue to pursue our business plan, we expect to finance our operations through both public and private sales of equity, debt financings or other commercial arrangements, which could include milestone payments from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties. However, there can be no assurance that any additional financing or strategic transactions will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we may need to delay, reduce or eliminate our product development or future commercialization efforts, which could have a material adverse effect on our business, results of operations or financial condition. Further, if we raise funds through licensing or other commercial arrangements with third parties, we may be required to relinquish valuable rights to our technology, future revenue streams, research programs or drug candidates or may be required to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock.

     

    Cash Flows

     

    The following table sets forth a summary of our cash flows for the periods indicated (in thousands):

     

        Three Months Ended  
        March 31,  
       

    2025

       

    2024

     

    Net cash used in operating activities

      $ (14,412 )   $ (7,975 )

    Net cash provided by investing activities

        14,915       8,731  

    Net cash provided by (used in) financing activities

        24       (18 )

    Net increase in cash and cash equivalents

      $ 527     $ 738  

     

    Operating Activities

     

    Net cash used in operating activities was $14.4 million for the three months ended March 31, 2025, which related to our net loss of $16.0 million and a $1.1 million change in operating assets and liabilities, partially offset by $2.7 million of non-cash charges for stock-based compensation, depreciation and amortization, accretion of premiums/discounts on investments, and non-cash operating lease expense. Net cash used in operating activities was $8.0 million for the three months ended March 31, 2024, which was due to our net loss of $8.4 million, partially offset by $0.1 million of non-cash charges such as stock-based compensation, depreciation and amortization, amortization of premiums/discounts on marketable securities and amortization of right-of-use assets and a $0.3 million change in operating assets and liabilities.

     

    Investing Activities

     

    Net cash provided by investing activities was $14.9 million for the three months ended March 31, 2025, which related to $48.7 million of sales and maturities of marketable securities, partially offset by $33.7 million of purchases of marketable securities. Net cash provided by investing activities was $8.7 million for the three months ended March 31, 2024, which consisted of $39.5 million of sales and maturities of marketable securities, partially offset by $30.7 million of purchases of marketable securities and $0.1 million of purchases of property and equipment.

     

    Financing Activities

     

    Net cash provided by financing activities was approximately $24,000 for the three months ended March 31, 2025, which related to proceeds from the exercise of stock options. Net cash used in financing activities was approximately $18,000 for the three months ended March 31, 2024, which was primarily due to payment of deferred offering costs offset by proceeds from the exercise of stock options. 

     

    Funding Requirements

     

    We expect our operating expenses to significantly increase as we continue to develop and seek regulatory approvals for our drug candidates, engage in other research and development activities to expand our pipeline of drug candidates, expand our operations and headcount, maintain and expand our intellectual property portfolio, and, if we obtain approval for one or more of our drug candidates, launch commercial activities. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and our actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing our drug candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.

     

    Our future capital requirements will depend on many factors, including:

     

     

    •

    the type, number, scope, progress, expansions, results, costs and timing of, our clinical trials and preclinical studies for our drug candidates or other potential drug candidates or indications which we are pursuing or may choose to pursue in the future;

     

     

    •

    the outcome, timing and costs of regulatory review of our drug candidates;

     

     

    •

    the costs and timing of manufacturing for our drug candidates;

     

     

    •

    our efforts to enhance our operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;

     

     

    •

    the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities expand;

     

     

    •

    the costs and timing of establishing or securing manufacturing facilities for our drug candidates;

     

    18

    Table of Contents

     

     

    •

    the costs and timing of establishing sales and marketing capabilities if any of our drug candidates are approved;

     

     

    •

    our ability to establish and maintain strategic collaborations, licensing or other arrangements;

     

     

    •

    the financial terms of any such agreements that we may enter into;

     

     

    •

    our decision to elect to fund a portion of Phase 3 and subsequent development costs for PIPE-307;

     

     

    •

    the costs of obtaining, maintaining and enforcing our patent and other intellectual property rights; and

     

     

    •

    costs associated with any drug candidates, products or technologies that we may in-license or acquire.

     

    Until such time as we can generate significant revenue from sales of our drug candidates, if ever, we expect to finance our cash needs through public or private equity or debt financings or other commercial arrangements, including collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties. We may be unable to raise additional funds or enter into such commercial arrangements when needed, on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may be required to relinquish valuable rights to our drug candidates, future revenue streams or research programs or may be required to grant licenses on terms that may not be favorable to us and may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or through commercial arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our drug candidates even if we would otherwise prefer to develop and market such drug candidates ourselves.

     

    Contractual Obligations and Commitments

     

    Our contractual obligations and commitments relate to our operating leases that relate primarily to our leases of office and laboratory space in San Diego, California. Our total contractual commitments for our lease agreements amount to approximately $7.3 million as of March 31, 2025.

     

    We enter into contracts in the normal course of business for contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above.

     

    Off-Balance Sheet Arrangements

     

    During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules and regulations of the SEC.

     

    Critical Accounting Policies and Significant Judgments and Estimates

     

    Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenue, and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, including those related to the accrual of research and development expenses; the incremental borrowing rate used to recognize the right-of-use assets and lease liabilities, the fair value of common stock and convertible preferred stock; and stock-based compensation We base our estimates and assumptions on historical experience, known trends and events, and various other factors that we believe are reasonable and appropriate under the circumstances, the results of which form the basis for making judgments about the carrying values of our assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

     

    There have been no material changes to our critical accounting estimates from those described under our “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Judgements and Estimates” included in our Annual Report on Form 10-K for the year ended December 31, 2024.

     

    Emerging growth company and smaller reporting company status

     

    We are an “emerging growth company”, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. We will remain an emerging growth company until the earlier of (i) December 31, 2029, the last day of the fiscal year following the fifth anniversary of the completion of the IPO, (ii) the last day of the fiscal year (a) in which we have total annual gross revenue of at least $1.235 billion or (b) in which we are deemed to be a large accelerated filer, which means the market value of our voting and non-voting common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

     

    We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter.

     

    19

    Table of Contents

     

    Item 3. Quantitative and Qualitative Disclosures About Market Risk.

     

    We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

     

    Item 4. Controls and Procedures.

     

    Evaluation of Disclosure Controls and Procedures

     

    Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of March 31, 2025, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

     

    Changes in Internal Control over Financial Reporting

     

    During the quarter ended March 31, 2025, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

     

    20

    Table of Contents
     

     

    PART II - OTHER INFORMATION

     

    Item 1. Legal Proceedings.

     

    From time to time, we may become involved in various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently a party to any material legal proceedings. Regardless of the outcome, litigation could have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

     

    Item 1A. Risk Factors.

     

    Investing in our common stock involves a high degree of risk. In addition to the information set forth in this Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our condensed financial statements and related notes, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on March 6, 2025. The occurrence of any of the risks and uncertainties described in such Annual Report could materially and adversely affect our business, financial condition, results of operations and prospects. In that event, the price of our common stock could decline and you could lose part or all of your investment. Furthermore, such risks are not the only ones we face; additional risks and uncertainties not currently known or that we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.

     

    21

    Table of Contents

     

    Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

     

    (a) Recent Sales of Unregistered Equity Securities.

     

    None.

     

    (b) Use of Proceeds from Initial Public Offering of Common Stock.

     

    On April 4, 2024, our registration statement on Form S-1 (333-278003) relating to the initial public offering of our common stock was declared effective by the SEC (the "Registration Statement"). Pursuant to such Registration Statement, we issued and sold an aggregate of 7,423,682 shares of our common stock, which includes 548,682 shares sold pursuant to the underwriters’ partial exercise of their option to purchase additional shares, at the public offering price of $16.00 per share. On April 9, 2024, we closed the sale of 6,875,000 shares and on April 19, 2024, we closed the sale of the 548,682 shares sold pursuant to the underwriters’ exercise of their option to purchase additional shares. The aggregate offering price for shares sold in the IPO was approximately $118.8 million, resulting in aggregate net proceeds of approximately $107.9 million, after deducting the underwriting discounts, commissions and offering expenses paid or payable by us. No offering expenses were paid or payable, directly or indirectly, to our directors, officers, persons owning 10% or more of any class of our equity securities, or to any of our affiliates. Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, Stifel Nicolaus & Company, Incorporated and RBC Capital Markets, LLC acted as joint book-running managers for the IPO.

     

    There has been no material change in the planned use of proceeds from the IPO from those described in the final Prospectus, dated April 4, 2024, filed with the SEC on April 8, 2024, pursuant to Rule 424(b) of the Securities Act.

     

    (c) Issuer Purchases of Equity Securities.

     

    None.

     

    Item 3. Defaults Upon Senior Securities.

     

    None.

     

    Item 4. Mine Safety Disclosures.

     

    Not Applicable.

     

     

    Item 5. Other Information.

     

    Trading Arrangements

     

    During the quarter ended  March 31, 2025, none of our directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).

     

    22

    Table of Contents
     
     

    Item 6. Exhibits

     

         

    Incorporated by Reference

    Filed Herewith

    Exhibit
    Number

     

    Description

    Form

    File No.

    Exhibit

    Filing Date

     
                   

    3.1

     

    Amended and Restated Certificate of Incorporation of the Registrant.

    8-K

    001-42001

    3.1

    04/09/2024

     

    3.2

     

    Amended and Restated Bylaws of the Registrant.

    8-K

    001-42001

    3.2

    04/09/2024

     
    10.1   Advisor Agreement, dated May, 31, 2024, by and between the Registrant and Diego Miralles.         X

     

    23

    Table of Contents

     

    31.1

     

    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

           

    X

    31.2

     

    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

           

    X

    32.1*

     

    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

           

    X

    32.2*

     

    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

           

    X

    101.INS

     

    Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

           

    X

    101.SCH

     

    Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.

           

    X

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

           

    X

    _________________________________________

    *    The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference.

     

    24

    Table of Contents

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

    Contineum Therapeutics, Inc.

     
           

    May 14, 2025

    By:

    /s/ Carmine Stengone

     
       

    Carmine Stengone

     
       

    President, Chief Executive Officer and Director

     
        (Principal Executive Officer)  

     

     

     

     
           
    May 14, 2025

    By:

    /s/ Peter Slover

     
       

    Peter Slover

     
       

    Chief Financial Officer

     
        (Principal Financial Officer and Principal Accounting Officer)  

     

     

    25
    Get the next $CTNM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    6/20/2025Outperform
    William Blair
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    SEC Filings

    See more
    • Contineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

      6/26/25 4:07:21 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Contineum Therapeutics Inc.

      EFFECT - Contineum Therapeutics, Inc. (0001855175) (Filer)

      5/27/25 12:15:13 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.

      SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)

      5/15/25 4:30:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Boyce Sarah

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:50:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schimmelpennink Evert B.

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:47:53 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brady Todd R.

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:46:34 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing. "In early June, consistent with our protocol, we enr

      6/25/25 8:15:00 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

      ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magni

      6/23/25 8:45:00 PM ET
      $ARTV
      $CTNM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI

      5/15/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Contineum Therapeutics

      William Blair initiated coverage of Contineum Therapeutics with a rating of Outperform

      6/20/25 7:53:37 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

      Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

      10/22/24 6:13:41 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Contineum Therapeutics Inc.

      SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

      11/14/24 4:38:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care